Evidence map›Paper›PMID 34458631›Full record

ArticleHeliyon2021

Trigenic

Shintaro Kinoshita, Miki Ando, Jun Ando, Midori Ishii, Yoshiki Furukawa, Osamu Tomita, Yoko Azusawa, Shuichi Shirane, Yoshihito Kishita, Yukiko Yatsuka and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Shintaro KinoshitaDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Miki AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Jun AndoDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Midori IshiiDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Yoshiki FurukawaDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Osamu TomitaDepartment of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan.
Yoko AzusawaDepartment of Transfusion Medicine and Stem Cell Regulation, Juntendo University School of Medicine, Tokyo, Japan.
Shuichi ShiraneDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Yoshihito KishitaDiagnostic and Therapeutics of Intractable Diseases, Graduate School of Medicine and Intractable Disease Research Center, Juntendo University, Tokyo, Japan.
Yukiko YatsukaDiagnostic and Therapeutics of Intractable Diseases, Graduate School of Medicine and Intractable Disease Research Center, Juntendo University, Tokyo, Japan.
Hidetaka EguchiDiagnostic and Therapeutics of Intractable Diseases, Graduate School of Medicine and Intractable Disease Research Center, Juntendo University, Tokyo, Japan.
Yasushi OkazakiDiagnostic and Therapeutics of Intractable Diseases, Graduate School of Medicine and Intractable Disease Research Center, Juntendo University, Tokyo, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Juntendo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Trio-next generation sequencing is useful to identify undiagnosed inherited diseases. We have attended a patient with trigenic

Indexed as

ADH5/ALDH/ADGRV1 variantsMyelodysplastic syndromeTrigenic mutationsTrio-next generation sequencingUsher syndrome

Identifiers

PMID34458631
PMCPMC8379464
OpenAlexW3195755430

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.